C5 and paroxysmal nocturnal hemoglobinuria: Ravulizumab showed non-inferiority compared with eculizumab in both adult patients with PNH naïve to complement inhibitors and in adult patients with PNH who had previously been treated with a C5 inhibitor [2, 7, 10, 12–14].